Tags

Type your tag names separated by a space and hit enter

Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls.
Arch Pathol Lab Med 2001; 125(4):510-2AP

Abstract

OBJECTIVE

To test the hypothesis that quantification of cerebrospinal fluid (CSF) F(2)-isoprostanes (F(2)-IsoPs), in vivo biomarkers of free radical damage, along with CSF Abeta(42) and tau levels improves laboratory diagnostic accuracy for Alzheimer disease (AD).

PARTICIPANTS

Patients with probable AD (n = 19), dementias other than AD (n = 8), and age-matched controls (n = 10).

MAIN OUTCOME MEASURES

Cerebrospinal fluid concentrations of Abeta(42) and tau were determined by a commercially available test (Athena Diagnostics, Worcester, Mass). Cerebrospinal fluid F(2)-IsoP levels were quantified by gas chromatography/mass spectrometry.

RESULTS

Individuals were classified as AD or non-AD by a published method using CSF Abeta(42) and tau levels (95% sensitivity, 50% specificity), by CSF F(2)-IsoP levels greater than 25 pg/mL and Abeta(42) concentrations less than 1125 pg/mL (90% sensitivity, 83% specificity), and by combined analysis using CSF F(2)-IsoP, Abeta(42), and tau levels (84% sensitivity, 89% specificity).

CONCLUSION

Cerebrospinal fluid F(2)-IsoP quantification may enhance the accuracy of the laboratory diagnosis of AD.

Authors+Show Affiliations

Department of Pathology, Vanderbilt University Medical Center, C3321-A Medical Center North, Nashville, TN 37232, USA. tom.montine@mcmail.vanderbilt.edu

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

11260625

Citation

Montine, T J., et al. "Cerebrospinal Fluid Abeta42, Tau, and F2-isoprostane Concentrations in Patients With Alzheimer Disease, Other Dementias, and in Age-matched Controls." Archives of Pathology & Laboratory Medicine, vol. 125, no. 4, 2001, pp. 510-2.
Montine TJ, Kaye JA, Montine KS, et al. Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Arch Pathol Lab Med. 2001;125(4):510-2.
Montine, T. J., Kaye, J. A., Montine, K. S., McFarland, L., Morrow, J. D., & Quinn, J. F. (2001). Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Archives of Pathology & Laboratory Medicine, 125(4), pp. 510-2.
Montine TJ, et al. Cerebrospinal Fluid Abeta42, Tau, and F2-isoprostane Concentrations in Patients With Alzheimer Disease, Other Dementias, and in Age-matched Controls. Arch Pathol Lab Med. 2001;125(4):510-2. PubMed PMID: 11260625.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. AU - Montine,T J, AU - Kaye,J A, AU - Montine,K S, AU - McFarland,L, AU - Morrow,J D, AU - Quinn,J F, PY - 2001/3/22/pubmed PY - 2001/5/1/medline PY - 2001/3/22/entrez SP - 510 EP - 2 JF - Archives of pathology & laboratory medicine JO - Arch. Pathol. Lab. Med. VL - 125 IS - 4 N2 - OBJECTIVE: To test the hypothesis that quantification of cerebrospinal fluid (CSF) F(2)-isoprostanes (F(2)-IsoPs), in vivo biomarkers of free radical damage, along with CSF Abeta(42) and tau levels improves laboratory diagnostic accuracy for Alzheimer disease (AD). PARTICIPANTS: Patients with probable AD (n = 19), dementias other than AD (n = 8), and age-matched controls (n = 10). MAIN OUTCOME MEASURES: Cerebrospinal fluid concentrations of Abeta(42) and tau were determined by a commercially available test (Athena Diagnostics, Worcester, Mass). Cerebrospinal fluid F(2)-IsoP levels were quantified by gas chromatography/mass spectrometry. RESULTS: Individuals were classified as AD or non-AD by a published method using CSF Abeta(42) and tau levels (95% sensitivity, 50% specificity), by CSF F(2)-IsoP levels greater than 25 pg/mL and Abeta(42) concentrations less than 1125 pg/mL (90% sensitivity, 83% specificity), and by combined analysis using CSF F(2)-IsoP, Abeta(42), and tau levels (84% sensitivity, 89% specificity). CONCLUSION: Cerebrospinal fluid F(2)-IsoP quantification may enhance the accuracy of the laboratory diagnosis of AD. SN - 0003-9985 UR - https://www.unboundmedicine.com/medline/citation/11260625/Cerebrospinal_fluid_abeta42_tau_and_f2_isoprostane_concentrations_in_patients_with_Alzheimer_disease_other_dementias_and_in_age_matched_controls_ L2 - http://www.archivesofpathology.org/doi/10.1043/0003-9985(2001)125<0510:CFATAF>2.0.CO;2?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -